|
Autologous stem cell transplantation in multiple myeloma patients over age 75. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
David Samuel DiCapua Siegel |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Karyopharm Therapeutics; Merck; Takeda |
Speakers' Bureau - Amgen; Celgene; Janssen Oncology; Takeda |
Research Funding - Celgene (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AmerisourceBergen; Express Scripts; McKesson |
Consulting or Advisory Role - Chimerix; Fate Therapeutics; Mesoblast |
Research Funding - Ansun Biopharma (Inst); Astellas Pharma (Inst); Chimerix (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Acerta Pharma; Celgene; Pharmacyclics; Takeda |
Consulting or Advisory Role - Acerta Pharma; Celgene; Infinity Pharmaceuticals; Pharmacyclics; Takeda |
Speakers' Bureau - Pharmacyclics; Takeda |
Research Funding - Clinical Trials Through Institution |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |